Abstract
Cladribine is a cytotoxic agent with high activity in hematological malignancies. It is usually administered intravenously. The study was carried out on 20 Egyptian hairy cell leukemia cases; 17 cases were de novo, and 3 cases were relapsed. Four (20%) were treated with IV cladribine, and 16 (80%) were treated with subcutaneous (SC) cladribine. An average duration of response was 36 months with no relapses in cases receiving IV cladribine vs. 25% relapse rate in cases receiving SC cladribine, with no significant difference between them. The subcutaneous administration of cladribine has a positive benefit/risk ratio in the treatment of patients with hairy cell leukemia.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
